Open Payments

California Pacific Medical Center

Type
Teaching hospital
Where
SAN FRANCISCO, CA
Medicare CCN
050047
Received
$1,529,832 in 132 records, 2022 ($30,845 general, $1,498,987 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2022General payment3$30,845
2022Research payment129$1,498,987

By company

CompanyRecordsAmountYears
Merck Sharp & Dohme LLC11$683,7482022
ModernaTX, Inc.13$434,0772022
Genentech, Inc.22$186,1312022
Regeneron Pharmaceuticals, Inc.21$58,8052022
Novocure Inc.3$50,1212022
Jenavalve Technology, Inc.1$28,4992022
AstraZeneca UK Limited3$21,3052022
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.2$20,8032022
Amgen Inc.1$9,9002022
AstraZeneca Pharmaceuticals LP1$9,7202022
UCB SA2$7,1632022
Medtronic, Inc.6$6,3512022
Partner Therapeutics, Inc.1$4,2002022
Alexion Pharmaceuticals, Inc.1$3,7502022
CSL Behring42$2,9102022
Chiesi USA, Inc.1$1,5002022
Siemens Medical Solutions USA, Inc.1$8452022

By nature of payment

NatureRecordsAmount
Research payment129$1,498,987
Compensation for services other than consulting, including serving as faculty or as a speaker at a v1$28,499
Space rental or facility fees (teaching hospital only)1$1,500
Gift1$845

Records

DateCompanyAmountNatureFormProductStudyYear
2022-12-31Merck Sharp & Dohme LLC$238,946Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini2022
2022-12-31Merck Sharp & Dohme LLC$105,369Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPhase II study of olaparib in combination with pembrolizumab in patients with advanced melanoma with homologous recombin2022
2022-12-31Merck Sharp & Dohme LLC$51,713Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection 2022
2022-12-31Merck Sharp & Dohme LLC$13,985Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini2022
2022-12-31Merck Sharp & Dohme LLC$13,562Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini2022
2022-12-31Merck Sharp & Dohme LLC$3,994Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection 2022
2022-12-31Merck Sharp & Dohme LLC$149Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg2022
2022-12-31AstraZeneca UK Limited$61Research paymentIn-kind items and servicesLYNPARZA Drug, OncologyOlaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene BRCA Mutated Ovarian Cancer Patients Who Have 2022
2022-12-31Merck Sharp & Dohme LLC$3Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection 2022
2022-12-22Genentech, Inc.$68,349Research paymentCash or cash equivalentOCREVUS Biological, ImmunologyA PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS2022
2022-12-21Regeneron Pharmaceuticals, Inc.$1,119Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2022
2022-12-20Genentech, Inc.$2,000Research paymentCash or cash equivalentCOTELLIC Drug, BioOncologyPHASE IB BELVARAFENIB ALONE AND IN COMBO WITH COBI OR COBI ATEZO IN NRAS M ADV MELANOMA PATIENTS2022
2022-12-19Merck Sharp & Dohme LLC$142,737Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini2022
2022-12-14Regeneron Pharmaceuticals, Inc.$2,000Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2022
2022-12-14Genentech, Inc.$54Research paymentCash or cash equivalent DrugABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC2022
2022-12-14Genentech, Inc.$27Research paymentCash or cash equivalent DrugABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC2022
2022-12-14Genentech, Inc.$27Research paymentCash or cash equivalent DrugABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC2022
2022-12-14Genentech, Inc.$27Research paymentCash or cash equivalent DrugABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC2022
2022-12-01Alexion Pharmaceuticals, Inc.$3,750Research paymentCash or cash equivalentA Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2052022
2022-11-29Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2022
2022-11-22Genentech, Inc.$4,450Research paymentCash or cash equivalentOCREVUS Biological, ImmunologyA PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS2022
2022-11-22AstraZeneca UK Limited$3,500Research paymentCash or cash equivalentA Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib and Doc2022
2022-11-22Regeneron Pharmaceuticals, Inc.$883Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2022
2022-11-21CSL Behring$72Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-11-21CSL Behring$54Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-11-21CSL Behring$36Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-11-21CSL Behring$36Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-11-21CSL Behring$36Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-11-21CSL Behring$36Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-11-15Regeneron Pharmaceuticals, Inc.$1,062Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2022
2022-11-08Regeneron Pharmaceuticals, Inc.$1,000Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2022
2022-11-07Novocure Inc.$6,512Research paymentCash or cash equivalentEF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi2022
2022-11-03Medtronic, Inc.$1,000Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsOptimize Pro2022
2022-10-28ModernaTX, Inc.$5,115Research paymentCash or cash equivalentA Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v2022
2022-10-12Regeneron Pharmaceuticals, Inc.$1,732Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2022
2022-10-06Genentech, Inc.$16,209Research paymentCash or cash equivalentOCREVUS Biological, ImmunologyA PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS2022
2022-09-29CSL Behring$207Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-09-29CSL Behring$116Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-09-29CSL Behring$50Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-09-29CSL Behring$28Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-09-29CSL Behring$25Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-09-29CSL Behring$23Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-09-29CSL Behring$16Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-09-29CSL Behring$7Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-09-29CSL Behring$4Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-09-29CSL Behring$3Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-09-23ModernaTX, Inc.$145,344Research paymentCash or cash equivalentA Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v2022
2022-09-23UCB SA$1,424Research paymentCash or cash equivalentPhase 3, Multicenter, Randomized, Double-Blind, PBO-Controlled Study of Efficacy, Safety, and Tolerability of Zilucoplan2022
2022-09-20Regeneron Pharmaceuticals, Inc.$1,232Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2022
2022-09-19Amgen Inc.$9,900Research paymentCash or cash equivalent2022
2022-09-18Merck Sharp & Dohme LLC$7,136Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection 2022
2022-09-14Medtronic, Inc.$475Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsOptimize Pro2022
2022-09-09Regeneron Pharmaceuticals, Inc.$883Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2022
2022-09-07Genentech, Inc.$2,750Research paymentCash or cash equivalent DrugABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC2022
2022-09-07Genentech, Inc.$2,700Research paymentCash or cash equivalent DrugABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC2022
2022-09-07Genentech, Inc.$500Research paymentCash or cash equivalent DrugABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC2022
2022-08-09Regeneron Pharmaceuticals, Inc.$1,289Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2022
2022-08-02UCB SA$5,738Research paymentCash or cash equivalentPhase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis2022
2022-07-27ModernaTX, Inc.$43,132Research paymentCash or cash equivalentA Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v2022
2022-07-21Regeneron Pharmaceuticals, Inc.$940Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2022
2022-06-30Regeneron Pharmaceuticals, Inc.$1,232Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2022
2022-06-16Genentech, Inc.$49,638Research paymentCash or cash equivalentOCREVUS Biological, ImmunologyA PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS2022
2022-06-16AstraZeneca Pharmaceuticals LP$9,720Research paymentCash or cash equivalentFARXIGA Drug, Cardiovascular and MetabolismDapagliflozin in Acute Decompensated Heart Failure2022
2022-06-16CSL Behring$360Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-06-16CSL Behring$180Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-06-16CSL Behring$144Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-06-16CSL Behring$126Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-06-16CSL Behring$126Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-06-16CSL Behring$126Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-06-16CSL Behring$126Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-06-16CSL Behring$120Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-06-16CSL Behring$104Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-06-16CSL Behring$104Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-06-16CSL Behring$52Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-06-16CSL Behring$48Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-06-16CSL Behring$30Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-06-16CSL Behring$18Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-06-16CSL Behring$10Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-06-16CSL Behring$3Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-06-14Genentech, Inc.$4,769Research paymentCash or cash equivalentCOTELLIC Drug, BioOncologyPHASE IB BELVARAFENIB ALONE AND IN COMBO WITH COBI OR COBI ATEZO IN NRAS M ADV MELANOMA PATIENTS2022
2022-06-14Genentech, Inc.$3,781Research paymentCash or cash equivalentCOTELLIC Drug, BioOncologyPHASE IB BELVARAFENIB ALONE AND IN COMBO WITH COBI OR COBI ATEZO IN NRAS M ADV MELANOMA PATIENTS2022
2022-06-14Genentech, Inc.$1,500Research paymentCash or cash equivalentCOTELLIC Drug, BioOncologyPHASE IB BELVARAFENIB ALONE AND IN COMBO WITH COBI OR COBI ATEZO IN NRAS M ADV MELANOMA PATIENTS2022
2022-06-02Regeneron Pharmaceuticals, Inc.$2,173Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2022
2022-05-19Regeneron Pharmaceuticals, Inc.$2,288Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2022
2022-05-11ModernaTX, Inc.$5,904Research paymentCash or cash equivalentA Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v2022
2022-05-11ModernaTX, Inc.$539Research paymentCash or cash equivalentA Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v2022
2022-05-09Merck Sharp & Dohme LLC$106,150Research paymentIn-kind items and servicesLYNPARZA Biological, ONCOLOGYPhase II study of olaparib in combination with pembrolizumab in patients with advanced melanoma with homologous recombin2022
2022-05-06CSL Behring$207Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-05-06CSL Behring$116Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-05-06CSL Behring$50Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-05-06CSL Behring$28Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-05-06CSL Behring$25Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-05-06CSL Behring$23Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-05-06CSL Behring$16Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-05-06CSL Behring$7Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-05-06CSL Behring$4Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-05-06CSL Behring$3Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2022
2022-05-05Chiesi USA, Inc.$1,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentCLEVIPREX Drug, CARDIOVASCULAR2022
2022-04-27Regeneron Pharmaceuticals, Inc.$2,116Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2022
2022-04-15ModernaTX, Inc.$2,733Research paymentCash or cash equivalentA Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v2022
2022-04-13ModernaTX, Inc.$3,200Research paymentCash or cash equivalentA Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v2022
2022-04-13ModernaTX, Inc.$3,000Research paymentCash or cash equivalentA Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v2022
2022-04-13Regeneron Pharmaceuticals, Inc.$1,767Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2022
2022-04-13ModernaTX, Inc.$500Research paymentCash or cash equivalentA Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v2022
2022-04-13ModernaTX, Inc.$500Research paymentCash or cash equivalentA Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v2022
2022-04-07Regeneron Pharmaceuticals, Inc.$4,084Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2022
2022-03-31BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.$20,130Research paymentCash or cash equivalentHealey Platform Trial2022
2022-03-31Siemens Medical Solutions USA, Inc.$845GiftCash or cash equivalentRAPIDPoint 400/405/500 Wash/Waste Cartridge Device, DX - Diagnostics incl. all products and services2022
2022-03-22Genentech, Inc.$21,206Research paymentCash or cash equivalentOCREVUS Biological, ImmunologyA PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS2022
2022-03-17Regeneron Pharmaceuticals, Inc.$2,809Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2022
2022-03-11Medtronic, Inc.$1,776Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsOptimize Pro2022
2022-03-10Regeneron Pharmaceuticals, Inc.$4,805Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2022
2022-03-10Regeneron Pharmaceuticals, Inc.$1,170Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2022
2022-03-03Genentech, Inc.$1,000Research paymentCash or cash equivalentCOTELLIC Drug, BioOncologyPHASE IB BELVARAFENIB ALONE AND IN COMBO WITH COBI OR COBI ATEZO IN NRAS M ADV MELANOMA PATIENTS2022
2022-03-02Genentech, Inc.$2,000Research paymentCash or cash equivalentCOTELLIC Drug, BioOncologyPHASE IB BELVARAFENIB ALONE AND IN COMBO WITH COBI OR COBI ATEZO IN NRAS M ADV MELANOMA PATIENTS2022
2022-03-02Genentech, Inc.$1,439Research paymentCash or cash equivalent DrugABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC2022
2022-02-28BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.$673Research paymentCash or cash equivalentHealey Platform Trial2022
2022-02-22Novocure Inc.$42,020Research paymentCash or cash equivalentEF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi2022
2022-02-14AstraZeneca UK Limited$17,743Research paymentCash or cash equivalentLYNPARZA Drug, OncologyOlaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene BRCA Mutated Ovarian Cancer Patients Who Have 2022
2022-02-03Regeneron Pharmaceuticals, Inc.$6,201Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2022
2022-02-03Partner Therapeutics, Inc.$4,200Research paymentCash or cash equivalentLEUKINE Drug, Hematology/OncologyiLEUK Pulm2022
2022-02-02Medtronic, Inc.$650Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsOptimize Pro2022
2022-01-28ModernaTX, Inc.$19,427Research paymentCash or cash equivalentA Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v2022
2022-01-26Genentech, Inc.$1,705Research paymentCash or cash equivalentAvastin Biological, BioOncologyA PHASE III OPEN LABEL RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB IN COMB2022
2022-01-26Genentech, Inc.$1,500Research paymentCash or cash equivalent DrugABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC2022
2022-01-26Genentech, Inc.$500Research paymentCash or cash equivalent DrugABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC2022
2022-01-25Novocure Inc.$1,587Research paymentCash or cash equivalentEF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi2022
2022-01-12ModernaTX, Inc.$163,091Research paymentCash or cash equivalentA Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v2022
2022-01-12ModernaTX, Inc.$41,588Research paymentCash or cash equivalentA Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v2022
2022-01-10Jenavalve Technology, Inc.$28,499Compensation for services other than consulting, including serving as faculty or as a speaker at a v (6 payments)Cash or cash equivalentJenaValve Pericardial TAVR System Device, Cardiology2022
2022-01-07Regeneron Pharmaceuticals, Inc.$18,013Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2022
2022-01-07Medtronic, Inc.$1,950Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2022

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

San Francisco CountySan Francisco city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.

MeasurePlace (city or town)
San Francisco, CA
County
San Francisco County, CA
State
California
Population B01003830,235830,23539,287,377
Population, 2020 census P1873,965873,96539,538,223
Median age B0100240.040.037.9
Under 18 B0100113.7%13.7%22.0%
65 and over B0100117.6%17.6%15.7%
Households B11001363,970363,97013,548,091
Foreign born B0500234.0%34.0%27.0%
Median household income B19013$140,970$140,970$99,122
Median family income B19113$171,141$171,141$113,346
Per capita income B19301$92,289$92,289$49,513
Poverty rate B1700111.2%11.2%12.0%
Unemployment rate B230256.1%6.1%6.6%
Civilian labor force B23025507,262507,26220,068,466
Mean commute (minutes) B0801330.430.428.7
Bachelor's degree or higher B1500360.3%60.3%37.1%
Housing units B25001414,602414,60214,644,735
Owner-occupied B2500338.2%38.2%55.9%
Renters B2500361.8%61.8%44.1%
Median home value B25077$1,394,500$1,394,500$734,700
Median gross rent B25064$2,476$2,476$2,036
White, not Hispanic B0300236.8%36.8%33.8%
Black B030024.7%4.7%5.2%
Hispanic or Latino B0300216.2%16.2%40.2%
Asian B0300234.9%34.9%15.3%
American Indian and Alaska Native B030020.2%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.0% in Oct 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.